Hak-Kim Chan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5771827/publications.pdf

Version: 2024-02-01

496 papers	20,433 citations	10956 71 h-index	26548 107 g-index
512 all docs	512 docs citations	512 times ranked	13685 citing authors

#	Article	IF	Citations
1	Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. Chinese Chemical Letters, 2023, 34, 107463.	4.8	5
2	The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery. Acta Pharmaceutica Sinica B, 2022, 12, 1460-1472.	5.7	18
3	Transformation of nanoparticles into compacts: A study on PLGA and celecoxib nanoparticles. International Journal of Pharmaceutics, 2022, 611, 121278.	2.6	9
4	Advances in the development of antimicrobial peptides and proteins for inhaled therapy. Advanced Drug Delivery Reviews, 2022, 180, 114066.	6.6	27
5	Effects of respiratory rate on the fluid mechanics of a reconstructed upper airway. Medical Engineering and Physics, 2022, 100, 103746.	0.8	3
6	Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline. Pharmaceutics, 2022, 14, 300.	2.0	16
7	The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clinical Microbiology and Infection, 2022, 28, 983-989.	2.8	14
8	Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. International Journal of Pharmaceutics, 2022, 616, 121507.	2.6	10
9	From laminar to turbulent flow in a dry powder inhaler: The effect of simple design modifications. International Journal of Pharmaceutics, 2022, 616, 121556.	2.6	5
10	Polymyxin Induces Significant Transcriptomic Perturbations of Cellular Signalling Networks in Human Lung Epithelial Cells. Antibiotics, 2022, 11, 307.	1.5	0
11	Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022, , .	0.7	3
12	Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022, 35, 73-82.	0.7	6
13	Pharmacokinetics and pharmacodynamics of peptide antibiotics. Advanced Drug Delivery Reviews, 2022, 183, 114171.	6.6	13
14	A dual action of D-amino acids on anti-biofilm activity and moisture-protection of inhalable ciprofloxacin powders. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 132-140.	2.0	7
15	Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment. International Journal of Pharmaceutics, 2022, 619, 121688.	2.6	4
16	Phageâ€“Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency. Antibiotics, 2022, 11, 570.	1.5	24
17	Topical liquid formulation of bacteriophages for metered-dose spray delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 1-8.	2.0	4
18	Novel antimicrobial agents for combating antibiotic-resistant bacteria. Advanced Drug Delivery Reviews, 2022, 187, 114378.	6.6	53

#	Article	IF	Citations
19	Inhalation delivery technology for genome-editing of respiratory diseases. Advanced Drug Delivery Reviews, 2021, 168, 217-228.	6.6	36
20	Synergistic activity of phage PEV20-ciprofloxacin combination powder formulationâ€"A proof-of-principle study in a P. aeruginosa lung infection model. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 166-171.	2.0	34
21	Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021, 34, 20-31.	0.7	16
22	Integrated Continuous Crystallization and Spray Drying of Insulin for Pulmonary Drug Delivery. Crystal Growth and Design, 2021, 21, 501-511.	1.4	12
23	Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection. Antibiotics, 2021, 10, 130.	1.5	36
24	Generation and characterization of electrostatically charged radiolabelled aerosols for lung scintigraphy. Aerosol Science and Technology, 2021, 55, 640-652.	1.5	2
25	Phage cocktail powder for Pseudomonas aeruginosa respiratory infections. International Journal of Pharmaceutics, 2021, 596, 120200.	2.6	27
26	Modeling of a spray drying method to produce ciprofloxacin nanocrystals inside the liposomes utilizing a response surface methodology: Box-Behnken experimental design. International Journal of Pharmaceutics, 2021, 597, 120277.	2.6	31
27	Concentration profile of tobramycin in exhaled breath condensate after inhalation of a single dose: A pilot study. Journal of Drug Delivery Science and Technology, 2021, 62, 102394.	1.4	6
28	Administration of dry powders during respiratory supports. Annals of Translational Medicine, 2021, 9, 596-596.	0.7	4
29	Dry powder pharmaceutical biologics for inhalation therapy. Advanced Drug Delivery Reviews, 2021, 172, 64-79.	6.6	53
30	Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery. International Journal of Pharmaceutics, 2021, 602, 120608.	2.6	6
31	A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols. International Journal of Pharmaceutics, 2021, 602, 120568.	2.6	16
32	Particle engineering principles and technologies for pharmaceutical biologics. Advanced Drug Delivery Reviews, 2021, 174, 140-167.	6.6	36
33	Polymyxin-Induced Metabolic Perturbations in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0083521.	1.4	3
34	Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages. International Journal of Pharmaceutics, 2021, 605, 120850.	2.6	15
35	Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharmaceutica Sinica B, 2021, 11, 2565-2584.	5.7	63
36	Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19. Pharmaceutics, 2021, 13, 1260.	2.0	11

#	Article	IF	Citations
37	Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes. International Journal of Pharmaceutics, 2021, 605, 120809.	2.6	13
38	Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. Viruses, 2021, 13, 1809.	1.5	15
39	Effect of inflow conditioning for dry powder inhalers. International Journal of Pharmaceutics, 2021, 608, 121085.	2.6	6
40	In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols. Advanced Drug Delivery Reviews, 2021, 177, 113952.	6.6	13
41	Lipid nanoparticles for the inhalation of mRNA. Nature Biomedical Engineering, 2021, 5, 949-950.	11.6	15
42	Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections. International Journal of Pharmaceutics, 2021, 609, 121206.	2.6	9
43	Raman spectroscopic evaluation of crystallinity, chemical composition and stability of pharmaceutical powder aerosols. International Journal of Pharmaceutics, 2021, 611, 121341.	2.6	6
44	Carboxymethyl fenugreek galactomannan-g-poly(N-isopropylacrylamide-co-N,Nâ€²-methylene-bis-acrylamide)-clay based pH/temperature-responsive nanocomposites as drug-carriers. Materials Science and Engineering C, 2020, 110, 110628.	3.8	27
45	Ultrafast star-shaped acoustic micromixer for high throughput nanoparticle synthesis. Lab on A Chip, 2020, 20, 582-591.	3.1	55
46	Polymeric Nanocarriers With Mucus-Diffusive and Mucus-Adhesive Properties to Control Pharmacokinetic Behavior of Orally Dosed Cyclosporine A. Journal of Pharmaceutical Sciences, 2020, 109, 1079-1085.	1.6	14
47	The effects of upper airway tissue motion on airflow dynamics. Journal of Biomechanics, 2020, 99, 109506.	0.9	13
48	Erlotinib-loaded carboxymethyl temarind gum semi-interpenetrating nanocomposites. Carbohydrate Polymers, 2020, 230, 115664.	5.1	20
49	Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria. International Journal of Pharmaceutics, 2020, 590, 119877.	2.6	10
50	Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs. International Journal of Pharmaceutics, 2020, 591, 119984.	2.6	11
51	Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	28
52	Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients. International Journal of Antimicrobial Agents, 2020, 56, 106199.	1.1	8
53	Can bacteriophage endolysins be nebulised for inhalation delivery against Streptococcus pneumoniae?. International Journal of Pharmaceutics, 2020, 591, 119982.	2.6	8
54	Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle. Pharmaceutical Research, 2020, 37, 219.	1.7	4

#	Article	IF	Citations
55	Cough as an adverse effect on inhalation pharmaceutical products. British Journal of Pharmacology, 2020, 177, 4096-4112.	2.7	19
56	Improved antibacterial efficiency of inhaled thiamphenicol dry powders: Mathematical modelling of in vitro dissolution kinetic and in vitro antibacterial efficacy. European Journal of Pharmaceutical Sciences, 2020, 152, 105435.	1.9	5
57	Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 283-289.	2.0	10
58	Enhancing Stability and Tooth Bleaching Activity of Carbamide Peroxide by Electrospun Nanofibrous Film. Pharmaceuticals, 2020, 13, 381.	1.7	8
59	Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections. International Journal of Pharmaceutics, 2020, 591, 119952.	2.6	14
60	Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-Î± siRNA with PAMAM dendrimers in a murine model. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 114-120.	2.0	49
61	Overcoming challenges for development of amorphous powders for inhalation. Expert Opinion on Drug Delivery, 2020, 17, 1583-1595.	2.4	18
62	Effects of the Glass-Forming Ability and Annealing Conditions on Cocrystallization Behaviors via Rapid Solvent Removal: A Case Study of Voriconazole. Pharmaceutics, 2020, 12, 1209.	2.0	10
63	Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols. Analytical Chemistry, 2020, 92, 8323-8332.	3.2	22
64	Quantitative comparison of three widely-used pulmonary administration methods in vivo with radiolabeled inhalable nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 108-115.	2.0	27
65	Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study. Clinical Microbiology and Infection, 2020, 26, 1229-1235.	2.8	33
66	In silico design and 3D printing of microfluidic chips for the preparation of size-controllable siRNA nanocomplexes. International Journal of Pharmaceutics, 2020, 583, 119388.	2.6	13
67	Nanoscale Probing of Liposome Encapsulating Drug Nanocrystal Using Atomic Force Microscopy-Infrared Spectroscopy. Analytical Chemistry, 2020, 92, 9922-9931.	3.2	12
68	Topical application of bacteriophages for treatment of wound infections. Translational Research, 2020, 220, 153-166.	2.2	50
69	Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 238-247.	2.0	28
70	In vivo deposition study of a new generation nebuliser utilising hybrid resonant acoustic (HYDRA) technology. International Journal of Pharmaceutics, 2020, 580, 119196.	2.6	9
71	In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation. Advanced Drug Delivery Reviews, 2020, 167, 135-147.	6.6	25
72	Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells. International Journal of Pharmaceutics, 2020, 586, 119570.	2.6	18

#	Article	IF	Citations
73	Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation. International Journal of Pharmaceutics, 2020, 578, 119045.	2.6	18
74	Predicting the composition and size distribution of dry particles for aerosols and sprays of suspension: A Monte Carlo approach. International Journal of Pharmaceutics, 2020, 582, 119311.	2.6	8
75	High frequency acoustic nebulization for pulmonary delivery of antibiotic alternatives against Staphylococcus aureus. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 151, 181-188.	2.0	18
76	Monoterpenes-containing PEGylated transfersomes for enhancing joint cavity drug delivery evidenced by CLSM and double-sited microdialysis. Materials Science and Engineering C, 2020, 113, 110929.	3.8	17
77	Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization. Bioengineering and Translational Medicine, 2020, 5, e10159.	3.9	35
78	Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. International Journal of Pharmaceutics, 2020, 585, 119441.	2.6	56
79	Potential effects of lingual fats on airway flow dynamics and particle deposition. Aerosol Science and Technology, 2020, 54, 321-331.	1.5	14
80	Microextraction and Chromatographic Analysis of Budesonide Epimers in Exhaled Breath Condensate. Current Analytical Chemistry, 2020, 16, 1032-1040.	0.6	0
81	Recent advances in electrospun for drug delivery purpose. Journal of Drug Targeting, 2019, 27, 270-282.	2.1	33
82	Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 543-552.	2.0	48
83	Integrated Continuous Plug-Flow Crystallization and Spray Drying of Pharmaceuticals for Dry Powder Inhalation. Industrial & Engineering Chemistry Research, 2019, 58, 16843-16857.	1.8	17
84	Anti-solvent Precipitation Method Coupled Electrospinning Process to Produce Poorly Water-Soluble Drug-Loaded Orodispersible Films. AAPS PharmSciTech, 2019, 20, 273.	1.5	18
85	In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 315-321.	2.0	9
86	Gastrointestinal Responsive Polymeric Nanoparticles for Oral Delivery of Insulin: Optimized Preparation, Characterization, and InÂVivo Evaluation. Journal of Pharmaceutical Sciences, 2019, 108, 2994-3002.	1.6	9
87	High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin. International Journal of Pharmaceutics, 2019, 572, 118818.	2.6	16
88	High Resolution Nanoscale Probing of Bacteriophages in an Inhalable Dry Powder Formulation for Pulmonary Infections. Analytical Chemistry, 2019, 91, 12760-12767.	3.2	12
89	Multiscale Computational Models for Respiratory Aerosol Dynamics with Medical Applications. Computational and Mathematical Methods in Medicine, 2019, 2019, 1-2.	0.7	1
90	Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. International Journal of Pharmaceutics, 2019, 566, 641-651.	2.6	47

#	Article	IF	Citations
91	Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders. International Journal of Pharmaceutics, 2019, 566, 32-39.	2.6	29
92	Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis. Journal of Drug Delivery Science and Technology, 2019, 52, 642-651.	1.4	58
93	CFD modelling of air and particle flows in different airway models. Journal of Aerosol Science, 2019, 134, 14-28.	1.8	33
94	Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. International Journal of Pharmaceutics, 2019, 565, 1-8.	2.6	41
95	How can the challenges faced by nanoparticle-based pulmonary drug formulations be overcome. Therapeutic Delivery, 2019, 10, 87-89.	1.2	1
96	Design of Inhalable Solid Dosage Forms of Budesonide and Theophylline for Pulmonary Combination Therapy. AAPS PharmSciTech, 2019, 20, 137.	1.5	16
97	Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring. Journal of Colloid and Interface Science, 2019, 545, 162-171.	5.0	21
98	Cocrystal Engineering of Itraconazole with Suberic Acid via Rotary Evaporation and Spray Drying. Crystal Growth and Design, 2019, 19, 2736-2745.	1.4	36
99	A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products. DARU, Journal of Pharmaceutical Sciences, 2019, 27, 517-524.	0.9	11
100	Overcoming Poor Tabletability of Bulky Absorption Enhancers byÂSpray Drying Technology. Journal of Pharmaceutical Sciences, 2019, 108, 2128-2135.	1.6	2
101	Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. AAPS Journal, 2019, 21, 49.	2.2	64
102	Encapsulation and release of doxycycline from electrospray-generated PLGA microspheres: Effect of polymer end groups. International Journal of Pharmaceutics, 2019, 564, 1-9.	2.6	63
103	Storage stability of inhalable phage powders containing lactose at ambient conditions. International Journal of Pharmaceutics, 2019, 560, 11-18.	2.6	46
104	Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition. International Journal of Pharmaceutics, 2019, 560, 144-154.	2.6	42
105	Spray-Dried Particles of Nitric Oxide-Modified Glutathione for the Treatment of Chronic Lung Infection. Molecular Pharmaceutics, 2019, 16, 1723-1731.	2.3	2
106	Aerosol drug delivery to the lungs during nasal high flow therapy: an in vitro study. BMC Pulmonary Medicine, 2019, 19, 42.	0.8	8
107	Amino acids as stabilizers for spray-dried simvastatin powder for inhalation. International Journal of Pharmaceutics, 2019, 572, 118724.	2.6	33
108	Does upper airway deformation affect drug deposition?. International Journal of Pharmaceutics, 2019, 572, 118773.	2.6	16

#	Article	IF	Citations
109	Molecular structure and impact of amorphization strategies on intrinsic dissolution of spray dried indomethacin. European Journal of Pharmaceutical Sciences, 2019, 129, 1-9.	1.9	16
110	Studies of Radioaerosol Deposition in the Respiratory Tract. Seminars in Nuclear Medicine, 2019, 49, 62-70.	2.5	10
111	Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation. Pharmaceutical Research, 2019, 36, 6.	1.7	14
112	Jet nebulization of bacteriophages with different tail morphologies â€“ Structural effects. International Journal of Pharmaceutics, 2019, 554, 322-326.	2.6	31
113	Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticles. Acta Pharmaceutica Sinica B, 2019, 9, 4-18.	5.7	124
114	Stability of lysozyme incorporated into electrospun fibrous mats for wound healing. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 240-249.	2.0	15
115	Evaluation of biomimetically synthesized mesoporous silica nanoparticles as drug carriers: Structure, wettability, degradation, biocompatibility and brain distribution. Materials Science and Engineering C, 2019, 94, 453-464.	3.8	59
116	Solid State Testing of Inhaled Formulations. , 2019, , 523-540.		0
117	Effect of storage temperature on the stability of spray dried bacteriophage powders. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 213-222.	2.0	57
118	Lipid Shell-Enveloped Polymeric Nanoparticles with High Integrity of Lipid Shells Improve Mucus Penetration and Interaction with Cystic Fibrosis-Related Bacterial Biofilms. ACS Applied Materials & Interfaces, 2018, 10, 10678-10687.	4.0	21
119	Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders. International Journal of Pharmaceutics, 2018, 541, 11-18.	2.6	18
120	Repurposing excipients as active inhalation agents: The mannitol story. Advanced Drug Delivery Reviews, 2018, 133, 45-56.	6.6	24
121	Nebulization effects on structural stability of bacteriophage PEV 44. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 124-130.	2.0	38
122	Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery. Pharmaceutical Research, 2018, 35, 5.	1.7	30
123	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
124	The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models. European Journal of Pharmaceutical Sciences, 2018, 115, 132-143.	1.9	10
125	Characterisation of 40â€¯mg/ml and 100â€¯mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. Pulmonary Pharmacology and Therapeutics, 2018, 50, 93-99.	1.1	4
126	Partitioning of dispersed nanoparticles in a realistic nasal passage for targeted drug delivery. International Journal of Pharmaceutics, 2018, 543, 83-95.	2.6	22

#	Article	IF	Citations
127	Biomimetic synthesis and evaluation of histidine-derivative templated chiral mesoporous silica for improved oral delivery of the poorly water-soluble drug, nimodipine. European Journal of Pharmaceutical Sciences, 2018, 117, 321-330.	1.9	22
128	Impact of molecular rearrangement of amphiphilic stabilizers on physical stability of itraconazole nanoparticles prepared by flash nanoprecipitation. International Journal of Pharmaceutics, 2018, 542, 221-231.	2.6	25
129	Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials, 2018, 151, 13-23.	5.7	175
130	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. International Journal of Pharmaceutics, 2018, 548, 740-746.	2.6	31
131	Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation. Carbohydrate Polymers, 2018, 181, 1143-1152.	5.1	59
132	Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	63
133	Pulmonary drug delivery to older people. Advanced Drug Delivery Reviews, 2018, 135, 50-61.	6.6	19
134	Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
135	Animal models of smoke inhalation injury and related acute and chronic lung diseases. Advanced Drug Delivery Reviews, 2018, 123, 107-134.	6.6	22
136	Ciprofloxacin-loaded sodium alginate/poly (lactic-co-glycolic acid) electrospun fibrous mats for wound healing. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 123, 42-49.	2.0	103
137	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Medicine Experimental, 2018, 6, 17.	0.9	7
138	Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying. Pharmaceutical Research, 2018, 35, 247.	1.7	21
139	Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms. International Journal of Pharmaceutics, 2018, 552, 130-138.	2.6	16
140	Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation. International Journal of Pharmaceutics, 2018, 552, 67-75.	2.6	38
141	Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa. International Journal of Pharmaceutics, 2018, 551, 158-165.	2.6	63
142	Effect of excipients on encapsulation and release of insulin from spray-dried solid lipid microparticles. International Journal of Pharmaceutics, 2018, 550, 439-446.	2.6	15
143	Insight into Nanoscale Network of Spray-Dried Polymeric Particles: Role of Polymer Molecular Conformation. ACS Applied Materials & Interfaces, 2018, 10, 36686-36692.	4.0	8
144	Poly(ethylene carbonate)-containing polylactic acid microparticles with rifampicin improve drug delivery to macrophages. Journal of Pharmacy and Pharmacology, 2018, 70, 1009-1021.	1.2	10

#	Article	IF	Citations
145	Influence of solvent mixtures on HPMCAS-celecoxib microparticles prepared by electrospraying. Asian Journal of Pharmaceutical Sciences, 2018, 13, 584-591.	4.3	3
146	Acoustically enhanced microfluidic mixer to synthesize highly uniform nanodrugs without the addition of stabilizers. International Journal of Nanomedicine, 2018, Volume 13, 1353-1359.	3.3	25
147	Biomedical application and controlled drug release of electrospun fibrous materials. Materials Science and Engineering C, 2018, 90, 750-763.	3.8	107
148	Polyester based nanovehicles for siRNA delivery. Materials Science and Engineering C, 2018, 92, 1006-1015.	3.8	20
149	Microfluidic-assisted bacteriophage encapsulation into liposomes. International Journal of Pharmaceutics, 2018, 545, 176-182.	2.6	35
150	Phage therapy for respiratory infections. Advanced Drug Delivery Reviews, 2018, 133, 76-86.	6.6	115
151	Inhaled non-steroidal polyphenolic alternatives for anti-inflammatory combination therapy. Powder Technology, 2018, 339, 244-255.	2.1	4
152	Mesoporous silicas templated by heterocyclic amino acid derivatives: Biomimetic synthesis and drug release application. Materials Science and Engineering C, 2018, 93, 407-418.	3.8	8
153	PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. PLoS ONE, 2018, 13, e0194620.	1.1	28
154	Crystal structure of aqua(2-{[2-({2-[bis(carboxylato-ÎºO-methyl)amino-ÎºN]ethyl}(carboxylato-ÎºO-methyl)amino-ÎºN)ethyl](carboxymethyl)azanium-1-yl}acetato trihydrate. Acta Crystallographica Section E: Crystallographic Communications, 2018, 74, 1054-1057.	0.4	1
155	Lack of a synergistic effect of arginineâ€“glutamic acid on the physical stability of spray-dried bovine serum albumin. Pharmaceutical Development and Technology, 2017, 22, 785-791.	1.1	11
156	Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles. AAPS Journal, 2017, 19, 578-586.	2.2	26
157	Electrospinnability of Poly Lactic-co-glycolic Acid (PLGA): the Role of Solvent Type and Solvent Composition. Pharmaceutical Research, 2017, 34, 738-749.	1.7	38
158	Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying. Journal of Pharmaceutical Sciences, 2017, 106, 1881-1888.	1.6	17
159	Effect of Spacers on the Bipolar Electrostatic Charge Properties of Metered Dose Inhaler Aerosolsâ€”A Case Study With TiladeÂ®. Journal of Pharmaceutical Sciences, 2017, 106, 1553-1559.	1.6	8
160	Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. International Journal of Pharmaceutics, 2017, 521, 141-149.	2.6	73
161	Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator. Carbohydrate Polymers, 2017, 172, 197-204.	5.1	36
162	Investigation of nanocarriers and excipients for preparation of nanoembedded microparticles. International Journal of Pharmaceutics, 2017, 526, 300-308.	2.6	11

#	Article	IF	Citations
163	Examining the ability of empirical correlations to predict subject specific in vivo extrathoracic aerosol deposition during tidal breathing. Aerosol Science and Technology, 2017, 51, 363-376.	1.5	20
164	Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. Journal of Controlled Release, 2017, 260, 78-91.	4.8	50
165	Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson's disease rat model. Journal of Pharmacy and Pharmacology, 2017, 69, 1110-1115.	1.2	14
166	Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	41
167	Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. Molecular Pharmaceutics, 2017, 14, 328-335.	2.3	15
168	Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	45
169	Investigation of factors affecting the stability of lysozyme spray dried from ethanol-water solutions. International Journal of Pharmaceutics, 2017, 534, 263-271.	2.6	9
170	Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 121, 1-13.	2.0	84
171	Powder aerosol delivery through nasal high-flow system: In vitro feasibility and influence of process conditions. International Journal of Pharmaceutics, 2017, 533, 187-197.	2.6	10
172	Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis. Molecular Pharmaceutics, 2017, 14, 3480-3488.	2.3	57
173	Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. International Journal of Pharmaceutics, 2017, 530, 40-52.	2.6	50
174	Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation. International Journal of Pharmaceutics, 2017, 530, 30-39.	2.6	46
175	The impact of particle preparation methods and polymorphic stability of lipid excipients on protein distribution in microparticles. Drug Development and Industrial Pharmacy, 2017, 43, 2032-2042.	0.9	3
176	Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 120, 9-21.	2.0	40
177	Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
178	Improved prediction of intersubject variability in extrathoracic aerosol deposition using algebraic correlations. Aerosol Science and Technology, 2017, 51, 667-673.	1.5	10
179	Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. Pharmaceutical Research, 2017, 34, 2084-2096.	1.7	71
180	Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 224-234.	2.0	43

#	Article	IF	Citations
181	A Novel In-Line Delivery System to Administer Dry Powder Mannitol to Mechanically Ventilated Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 100-107.	0.7	7
182	Inhaler Technique in Asthma: How Does It Relate to Patients' Preferences and Attitudes Toward Their Inhalers?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 42-52.	0.7	46
183	Inhalable clarithromycin liposomal dry powders using ultrasonic spray freeze drying. Powder Technology, 2017, 305, 63-70.	2.1	40
184	The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. AAPS Journal, 2017, 19, 191-202.	2.2	15
185	Monitoring the Inhalation Flow Rate of Nebulized Aerosols Using an Ultrasonic Flow Meter:In VitroAssessment. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 173-181.	0.7	2
186	New nano-matrix oral formulation of nanoprecipitated cyclosporine A prepared with multi-inlet vortex mixer. International Journal of Pharmaceutics, 2017, 516, 116-119.	2.6	12
187	The Effects of Relative Humidity on the Flowability and Dispersion Performance of Lactose Mixtures. Materials, 2017, 10, 592.	1.3	30
188	Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols. Pharmaceutical Research, 2017, 34, 1707-1715.	1.7	10
189	Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation. Pharmaceutical Research, 2016, 33, 2107-2116.	1.7	9
190	Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews, 2016, 102, 83-101.	6.6	60
191	Atomized Human Amniotic Mesenchymal Stromal Cells for Direct Delivery to the Airway for Treatment of Lung Injury. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 514-524.	0.7	20
192	Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. European Journal of Pharmaceutical Sciences, 2016, 88, 1-11.	1.9	42
193	Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. Pharmaceutical Research, 2016, 33, 1486-1496.	1.7	106
194	How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?. AAPS Journal, 2016, 18, 1213-1224.	2.2	42
195	Fundamentals of aerosol therapy in critical care. Critical Care, 2016, 20, 269.	2.5	78
196	Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose. International Journal of Pharmaceutics, 2016, 511, 1070-1079.	2.6	16
197	Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug. Pharmaceutical Research, 2016, 33, 2748-2762.	1.7	20
198	The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder. International Journal of Pharmaceutics, 2016, 513, 294-301.	2.6	18

#	Article	IF	Citations
199	In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs. International Journal of Pharmaceutics, 2016, 513, 211-217.	2.6	20
200	Effect of ethanol as a co-solvent on the aerosol performance and stability of spray-dried lysozyme. International Journal of Pharmaceutics, 2016, 513, 175-182.	2.6	20
201	In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 205-214.	2.0	12
202	Apomorphine and its esters: Differences in Caco-2 cell permeability and chylomicron affinity. International Journal of Pharmaceutics, 2016, 509, 499-506.	2.6	16
203	Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure. AAPS Journal, 2016, 18, 1159-1167.	2.2	14
204	Formation of drug nanocrystals under nanoconfinement afforded by liposomes. RSC Advances, 2016, 6, 6223-6233.	1.7	38
205	Amorphous powders for inhalation drug delivery. Advanced Drug Delivery Reviews, 2016, 100, 102-115.	6.6	146
206	A Proof-of-Principle Setup for Delivery of Relenza^{Â®} (Zanamivir) Inhalation Powder to Intubated Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 30-35.	0.7	8
207	Bipolar electrostatic charge and mass distributions of powder aerosolsÂâ€“ Effects of inhaler design and inhaler material. Journal of Aerosol Science, 2016, 95, 104-117.	1.8	6
208	Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. Pharmaceutical Research, 2016, 33, 1447-1455.	1.7	9
209	In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy. Molecular Pharmaceutics, 2016, 13, 979-989.	2.3	18
210	CFDâ€“DEM investigation of the effect of agglomerateâ€“agglomerate collision on dry powder aerosolisation. Journal of Aerosol Science, 2016, 92, 109-121.	1.8	36
211	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases. Journal of Pharmaceutical Sciences, 2016, 105, 650-656.	1.6	27
212	l -Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102, 132-141.	2.0	135
213	Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin. AAPS Journal, 2016, 18, 372-384.	2.2	43
214	Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. International Journal of Pharmaceutics, 2016, 498, 82-95.	2.6	75
215	Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. European Journal of Pharmaceutical Sciences, 2016, 84, 46-54.	1.9	33
216	Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. Journal of Antimicrobial Chemotherapy, 2016, 71, 403-412.	1.3	52

#	Article	IF	Citations
217	Applicability of Bipolar Charge Analyzer (BOLAR) in Characterizing the Bipolar Electrostatic Charge Profile of Commercial Metered Dose Inhalers (MDIs). Pharmaceutical Research, 2016, 33, 283-291.	1.7	10
218	Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opinion on Drug Delivery, 2016, 13, 7-22.	2.4	18
219	Pulmonary Delivery of Antibiotics for Respiratory Infections. , 2016, , 131-150.		0
220	Inhaled Therapeutic siRNA for the Treatment of Respiratory Diseases. , 2016, , 31-48.		0
221	In-Vitro Characterization and Oral Bioavailability of Organic Solvent-free Solid Dispersions Containing Telmisartan. Iranian Journal of Pharmaceutical Research, 2016, 15, 385-94.	0.3	5
222	Measuring Bipolar Charge and Mass Distributions of Powder Aerosols by a Novel Tool (BOLAR). Molecular Pharmaceutics, 2015, 12, 3433-3440.	2.3	15
223	Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer. Scientific Reports, 2015, 5, 11878.	1.6	46
224	Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 411-422.	0.7	23
225	Editorial (Thematic Issue: Emerging Formulation Design and Drug Delivery Systems for Inhaled) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	0
226	Computational fluid dynamics (CFD) investigation of the gasâ€“solid flow and performance of Andersen cascade impactor. Powder Technology, 2015, 285, 128-137.	2.1	8
227	Lipophilic prodrugs of apomorphine I: Preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 216-223.	2.0	32
228	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents, 2015, 45, 319-323.	1.1	14
229	The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering. Expert Opinion on Drug Delivery, 2015, 12, 869-887.	2.4	13
230	Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections. Molecular Pharmaceutics, 2015, 12, 2594-2603.	2.3	23
231	Isothermal Microcalorimetry of Pressurized Systems II: Effect of Excipient and Water Ingress on Formulation Stability of Amorphous Glycopyrrolate. Pharmaceutical Research, 2015, 32, 714-722.	1.7	2
232	A novel inhaled multi-pronged attack against respiratory bacteria. European Journal of Pharmaceutical Sciences, 2015, 70, 37-44.	1.9	17
233	Inhalable Dry Powder Formulations of siRNA and pH-Responsive Peptides with Antiviral Activity Against H1N1 Influenza Virus. Molecular Pharmaceutics, 2015, 12, 910-921.	2.3	41
234	Multi-Scale Modelling of Powder Dispersion in a Carrier-Based Inhalation System. Pharmaceutical Research, 2015, 32, 2086-2096.	1.7	38

#	Article	IF	Citations
235	Pharmaceutical microparticle engineering with electrospraying: the role of mixed solvent systems in particle formation and characteristics. Journal of Materials Science: Materials in Medicine, 2015, 26, 61.	1.7	29
236	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. Pharmaceutical Research, 2015, 32, 2928-2936.	1.7	5
237	An Apparatus to Deliver Mannitol Powder for Bronchial Provocation in Children Under Six Years Old. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 452-461.	0.7	2
238	Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Advanced Drug Delivery Reviews, 2015, 85, v-vii.	6.6	0
239	De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products. AAPS Journal, 2015, 17, 1407-1416.	2.2	30
240	Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead. Advanced Drug Delivery Reviews, 2015, 85, 65-82.	6.6	75
241	Investigation of protein distribution in solid lipid particles and its impact on protein release using coherent anti-Stokes Raman scattering microscopy. Journal of Controlled Release, 2015, 197, 111-120.	4.8	19
242	Electrostatics in pharmaceutical solids. Chemical Engineering Science, 2015, 125, 225-237.	1.9	50
243	Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Advanced Drug Delivery Reviews, 2015, 85, 83-99.	6.6	198
244	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Development and Industrial Pharmacy, 2015, 41, 859-865.	0.9	20
245	The Effect of Actuator Nozzle Designs on the Electrostatic Charge Generated in Pressurised Metered Dose Inhaler Aerosols. Pharmaceutical Research, 2015, 32, 1237-1248.	1.7	4
246	A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers. Current Pharmaceutical Design, 2015, 21, 3955-3965.	0.9	5
247	Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review. Current Pharmaceutical Design, 2015, 21, 3966-3973.	0.9	25
248	Powder Production and Particle Engineering for Dry Powder Inhaler Formulations. Current Pharmaceutical Design, 2015, 21, 3902-3916.	0.9	69
249	In VitroAssessment of Dose Delivery Performance of Dry Powders for Inhalation. Aerosol Science and Technology, 2014, 48, 1099-1110.	1.5	30
250	Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. Journal of Pharmaceutical Sciences, 2014, 103, 314-327.	1.6	49
251	Steroid-Decorated Antibiotic Microparticles for Inhaled Anti-Infective Therapy. Journal of Pharmaceutical Sciences, 2014, 103, 1115-1125.	1.6	14
252	Crystallization of Piroxicam Solid Forms and the Effects of Additives. Chemical Engineering and Technology, 2014, 37, 1297-1304.	0.9	19

#	Article	IF	Citations
253	Nanodrugs: pharmacokinetics and safety. International Journal of Nanomedicine, 2014, 9, 1025.	3.3	274
254	Overcoming Dose Limitations Using the Orbital^{Â®} Multi-Breath Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 138-147.	0.7	42
255	Delivery of inhalation drugs to children for asthma and other respiratory diseases. Advanced Drug Delivery Reviews, 2014, 73, 83-88.	6.6	38
256	The Influence of Actuator Materials and Nozzle Designs on Electrostatic Charge of Pressurised Metered Dose Inhaler (pMDI) Formulations. Pharmaceutical Research, 2014, 31, 1325-1337.	1.7	10
257	One-Step Production of Protein-Loaded PLGA Microparticles via Spray Drying Using 3-Fluid Nozzle. Pharmaceutical Research, 2014, 31, 1967-1977.	1.7	41
258	A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. Pharmaceutical Research, 2014, 31, 1239-1253.	1.7	44
259	Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 64-73.	2.0	49
260	Emerging inhalation aerosol devices and strategies: Where are we headed?. Advanced Drug Delivery Reviews, 2014, 75, 3-17.	6.6	160
261	Pulmonary drug delivery by powder aerosols. Journal of Controlled Release, 2014, 193, 228-240.	4.8	151
262	Advances in Device and Formulation Technologies for Pulmonary Drug Delivery. AAPS PharmSciTech, 2014, 15, 882-897.	1.5	63
263	Effect of Crystallinity on Electrostatic Charging in Dry Powder Inhaler Formulations. Pharmaceutical Research, 2014, 31, 1656-1664.	1.7	26
264	Modifying the Release Properties of Liposomes Toward Personalized Medicine. Journal of Pharmaceutical Sciences, 2014, 103, 1851-1862.	1.6	49
265	Predicting physical stability in pressurized metered dose inhalers via dwell and instantaneous force colloidal probe microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 129-135.	2.0	6
266	Isothermal Microcalorimetry of Pressurized Systems I: A Rapid Method to Evaluate Pressurized Metered Dose Inhaler Formulations. Pharmaceutical Research, 2014, 31, 2716-2723.	1.7	4
267	NanoXCT: A Novel Technique to Probe the Internal Architecture of Pharmaceutical Particles. Pharmaceutical Research, 2014, 31, 3085-3094.	1.7	13
268	Synergistic Antibiotic Combination Powders of Colistin and Rifampicin Provide High Aerosolization Efficiency and Moisture Protection. AAPS Journal, 2014, 16, 37-47.	2.2	69
269	Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. AAPS PharmSciTech, 2014, 15, 1218-1227.	1.5	17
270	Attachment of micro- and nano-particles on tipless cantilevers for colloidal probe microscopy. Journal of Colloid and Interface Science, 2014, 426, 190-198.	5.0	9

#	Article	IF	Citations
271	A Novel Inhalable Form of Rifapentine. Journal of Pharmaceutical Sciences, 2014, 103, 1411-1421.	1.6	43
272	Quantitative and Qualitative Examination of Particle-particle Interactions Using Colloidal Probe Nanoscopy. Journal of Visualized Experiments, 2014, , .	0.2	1
273	Current Advances and Future Trends in Characterizing Poorly Water-soluble Drugs Using Spectroscopic, Imaging and Data Analytical Techniques. Current Pharmaceutical Design, 2014, 20, 436-453.	0.9	11
274	Application of Spray-drying and Electrospraying/Electospinning for Poorly Watersoluble Drugs: A Particle Engineering Approach. Current Pharmaceutical Design, 2014, 20, 325-348.	0.9	38
275	Nanotechnology Versus other Techniques in Improving Drug Dissolution. Current Pharmaceutical Design, 2014, 20, 474-482.	0.9	36
276	High speed imaging with electrostatic charge monitoring to track powder deagglomeration upon impact. Journal of Aerosol Science, 2013, 65, 77-87.	1.8	12
277	Electrostatics in pharmaceutical aerosols for inhalation. Therapeutic Delivery, 2013, 4, 981-1002.	1.2	33
278	Liposomal formulations for inhalation. Therapeutic Delivery, 2013, 4, 1047-1072.	1.2	120
279	Aerosol Delivery of Nanoparticles in Uniform Mannitol Carriers Formulated by Ultrasonic Spray Freeze Drying. Pharmaceutical Research, 2013, 30, 2891-2901.	1.7	55
280	TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine, 2013, 31, 4322-4329.	1.7	59
281	Effects of mechanical impaction on aerosol performance of particles with different surface roughness. Powder Technology, 2013, 236, 164-170.	2.1	31
282	Pulmonary drug delivery. Therapeutic Delivery, 2013, 4, 877-878.	1.2	6
283	Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 275-284.	2.0	31
284	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Development and Industrial Pharmacy, 2013, 39, 1625-1637.	0.9	26
285	Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01. Journal of Controlled Release, 2013, 167, 256-264.	4.8	38
286	Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology, 2013, 38, 612-625.	1.3	313
287	CFD-DEM investigation of the dispersion mechanisms in commercial dry powder inhalers. Powder Technology, 2013, 240, 19-24.	2.1	97
288	Inhaled antibiotics to treat lung infection. Pharmaceutical Patent Analyst, 2013, 2, 647-663.	0.4	44

#	Article	IF	Citations
289	Unitary hormonal models, peripheral markers, and evaluation of response to drug: A response to Weisman and Feldman. Psychoneuroendocrinology, 2013, 38, 627-628.	1.3	2
290	Critical Solvent Properties Affecting the Particle Formation Process and Characteristics of Celecoxib-Loaded PLGA Microparticles via Spray-Drying. Pharmaceutical Research, 2013, 30, 1065-1076.	1.7	59
291	Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. International Journal of Pharmaceutics, 2013, 452, 194-200.	2.6	22
292	The production of dry powder by the sonocrystallisation for inhalation drug delivery. Powder Technology, 2013, 246, 337-344.	2.1	9
293	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 285-292.	2.0	86
294	Effect of Device Design on the Aerosolization of a Carrier-Based Dry Powder Inhalerâ€"a Case Study on AerolizerÂ® ForadileÂ®. AAPS Journal, 2013, 15, 511-522.	2.2	62
295	Visualizing powder de-agglomeration upon impact with simultaneous flowing charge behaviour. , 2013, , .		0
296	Synergistic combination dry powders for inhaled antimicrobial therapy. , 2013, , .		1
297	Colistin Powders with High Aerosolisation Efficiency for Respiratory Infection: Preparation and In Vitro Evaluation. Journal of Pharmaceutical Sciences, 2013, 102, 3736-3747.	1.6	49
298	CFD analysis of the aerosolization of carrier-based dry powder inhaler formulations. , 2013, , .		4
299	Delivery of High Solubility Polyols by Vibrating Mesh Nebulizer to Enhance Mucociliary Clearance. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 297-305.	0.7	12
300	Formulation technologies to overcome unfavorable properties of peptides and proteins for pulmonary delivery. Drug Discovery Today: Technologies, 2012, 9, e141-e146.	4.0	25
301	The effect of lactose micro-spherical crystals prepared by conditioning with supercritical fluid on salbutamol sulphate inhalation performance. Journal of Supercritical Fluids, 2012, 71, 92-101.	1.6	9
302	Validation of Radiolabeling of Drug Formulations for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, S-6-S-9.	0.7	32
303	Standardization of Techniques for Using Single-Photon Emission Computed Tomography (SPECT) for Aerosol Deposition Assessment of Orally Inhaled Products. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, S-29-S-51.	0.7	32
304	Safety Of Administering Dry Powder Mannitol To Stimulate Sputum Clearance In Intubated Intensive Care Patients With Sputum Retention: A Pilot Study. , 2012, , .		2
305	Does the United States Pharmacopeia Throat Introduce De-agglomeration of Carrier-Free Powder from Inhalers?. Pharmaceutical Research, 2012, 29, 1797-1807.	1.7	22
306	Pulmonary delivery of therapeutic siRNA. Advanced Drug Delivery Reviews, 2012, 64, 1-15.	6.6	177

#	Article	IF	Citations
307	A critical view on lactose-based drug formulation and device studies for dry powder inhalation: Which are relevant and what interactions to expect?. Advanced Drug Delivery Reviews, 2012, 64, 257-274.	6.6	141
308	The use of computational approaches in inhaler development. Advanced Drug Delivery Reviews, 2012, 64, 312-322.	6.6	69
309	Constant size, variable density aerosol particles by ultrasonic spray freeze drying. International Journal of Pharmaceutics, 2012, 427, 185-191.	2.6	63
310	Design and evaluation of poly(dl-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. European Journal of Pharmaceutical Sciences, 2012, 46, 374-380.	1.9	41
311	Design and evaluation of inhalable chitosan-modified poly (dl-lactic-co-glycolic acid) nanocomposite particles. European Journal of Pharmaceutical Sciences, 2012, 47, 235-243.	1.9	33
312	Assessing the combinatorial influence of climate, formulation and device on powder aerosolization using the Taguchi experimental design. Powder Technology, 2012, 226, 253-260.	2.1	19
313	Stabilization of liposomes during drying. Expert Opinion on Drug Delivery, 2011, 8, 375-388.	2.4	114
314	Agglomerate strength and dispersion of pharmaceutical powders. Journal of Aerosol Science, 2011, 42, 285-294.	1.8	32
315	Numerical investigation of the de-agglomeration mechanisms of fine powders on mechanical impaction. Journal of Aerosol Science, 2011, 42, 811-819.	1.8	30
316	Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. International Journal of Pharmaceutics, 2011, 420, 34-42.	2.6	67
317	Particle size dependence of polymorphism in spray-dried mannitol. European Journal of Pharmaceutical Sciences, 2011, 44, 41-48.	1.9	51
318	Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. European Journal of Pharmaceutical Sciences, 2011, 44, 610-620.	1.9	68
319	Formation, characterization, and fate of inhaled drug nanoparticles. Advanced Drug Delivery Reviews, 2011, 63, 441-455.	6.6	175
320	Production methods for nanodrug particles using the bottom-up approach. Advanced Drug Delivery Reviews, 2011, 63, 406-416.	6.6	351
321	Nanodrug particles and nanoformulations for drug delivery. Advanced Drug Delivery Reviews, 2011, 63, 405.	6.6	16
322	Formulating Biomolecules: Mechanistics Insights in Molecular Interactions. Advanced Drug Delivery Reviews, 2011, 63, 1051-1052.	6.6	2
323	Formation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug Delivery. Pharmaceutical Research, 2011, 28, 788-796.	1.7	35
324	Mannitol Delivery by Vibrating Mesh Nebulisation for Enhancing Mucociliary Clearance. Journal of Pharmaceutical Sciences, 2011, 100, 2693-2702.	1.6	13

#	Article	IF	Citations
325	Particle Aerosolisation and Break-Up in Dry Powder Inhalers: Evaluation and Modelling of Impaction Effects for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 2744-2754.	1.6	21
326	Particle Aerosolisation and Breakâ€up in Dry Powder Inhalers: Evaluation and Modelling of the Influence of Grid Structures for Agglomerated Systems. Journal of Pharmaceutical Sciences, 2011, 100, 4710-4721.	1.6	25
327	Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. International Journal of Pharmaceutics, 2011, 403, 192-200.	2.6	333
328	Method to Introduce Mannitol Powder to Intubated Patients to Improve Sputum Clearance. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2011, 24, 1-9.	0.7	26
329	Isoniazid Proliposome Powders for Inhalationâ€"Preparation, Characterization and Cell Culture Studies. International Journal of Molecular Sciences, 2011, 12, 4414-4434.	1.8	92
330	Pulmonary Delivery of Peptides and Proteins. , 2011, , 23-46.		9
331	Pure drug nanoparticles in tablets: what are the dissolution limitations?. Journal of Nanoparticle Research, 2010, 12, 1743-1754.	0.8	27
332	The Contribution of Different Formulation Components on the Aerosol Charge in Carrier-Based Dry Powder Inhaler Systems. Pharmaceutical Research, 2010, 27, 1325-1336.	1.7	18
333	Particle Aerosolisation and Break-up in Dry Powder Inhalers 1: Evaluation and Modelling of Venturi Effects for Agglomerated Systems. Pharmaceutical Research, 2010, 27, 1367-1376.	1.7	50
334	Can low-dose combination products for inhalation be formulated in single crystalline particles?. European Journal of Pharmaceutical Sciences, 2010, 40, 16-24.	1.9	32
335	Co-spray-dried mannitolâ€"ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. European Journal of Pharmaceutical Sciences, 2010, 40, 239-247.	1.9	90
336	Impact angles as an alternative way to improve aerosolisation of powders for inhalation?. European Journal of Pharmaceutical Sciences, 2010, 41, 320-327.	1.9	19
337	Does electrostatic charge affect powder aerosolisation?. Journal of Pharmaceutical Sciences, 2010, 99, 2455-2461.	1.6	23
338	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 853-857.	1.4	23
339	A novel method for the production of crystalline micronised particles. International Journal of Pharmaceutics, 2010, 388, 114-122.	2.6	24
340	Numerical study of the effects of particle size and polydispersity on the agglomerate dispersion in a cyclonic flow. Chemical Engineering Journal, 2010, 164, 432-441.	6.6	77
341	Controlled release antibiotics for dry powder lung delivery. Drug Development and Industrial Pharmacy, 2010, 36, 119-126.	0.9	51
342	Electrostatic Charge Characteristics of Jet Nebulized Aerosols. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 149-159.	0.7	24

#	Article	IF	Citations
343	Personalizing aerosol medicine: development of delivery systems tailored to the individual. Therapeutic Delivery, 2010, 1, 667-682.	1.2	30
344	Electrostatics of pharmaceutical inhalation aerosols. Journal of Pharmacy and Pharmacology, 2010, 61, 1587-1599.	1.2	30
345	Pulmonary Formulations: What Remains to be Done?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, S-5-S-23.	0.7	91
346	Numerical Study of Effects of Powder Size and Polydispersity on the Dispersion of Fine Powders in a Cyclonic Flow. , 2009, , .		0
347	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). European Journal of Pharmaceutical Sciences, 2009, 38, 88-94.	1.9	47
348	Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation. Journal of Pharmaceutical Sciences, 2009, 98, 628-639.	1.6	88
349	Preparation and Evaluation of Controlled Release Microparticles for Respiratory Protein Therapy. Journal of Pharmaceutical Sciences, 2009, 98, 2709-2717.	1.6	34
350	Validation of computation method to predict aerodynamic diameter of particles with rough surface. Powder Technology, 2009, 192, 74-84.	2.1	8
351	Introduction of the Electrical Next Generation Impactor (eNGI) and Investigation of its Capabilities for the Study of Pressurized Metered Dose Inhalers. Pharmaceutical Research, 2009, 26, 431-437.	1.7	32
352	Lactose Composite Carriers for Respiratory Delivery. Pharmaceutical Research, 2009, 26, 802-810.	1.7	49
353	The Influence of Flow Rate on the Aerosol Deposition Profile and Electrostatic Charge of Single and Combination Metered Dose Inhalers. Pharmaceutical Research, 2009, 26, 2639-2646.	1.7	36
354	Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. International Journal of Pharmaceutics, 2009, 367, 51-57.	2.6	28
355	Numerical modelling of the breakage of loose agglomerates of fine particles. Powder Technology, 2009, 196, 213-221.	2.1	82
356	Development of an In Vivo Ovine Dry Powder Inhalation Model for the Evaluation of Conventional and Controlled Release Microparticles. AAPS Journal, 2009, 11, 465-8.	2.2	7
357	Recent Advances in Controlled Release Pulmonary Therapy. Current Drug Delivery, 2009, 6, 404-414.	0.8	22
358	Controlled release antibiotics for dry powder lung delivery. Drug Development and Industrial Pharmacy, 2009, 00, 090805050810080-8.	0.9	1
359	Electrostatics of pharmaceutical inhalation aerosols. Journal of Pharmacy and Pharmacology, 2009, 61, 1587-1599.	1.2	13
360	Effect of Relative Humidity on the Electrostatic Charge Properties of Dry Powder Inhaler Aerosols. Pharmaceutical Research, 2008, 25, 277-288.	1.7	63

#	Article	IF	Citations
361	What is a Suitable Dissolution Method for Drug Nanoparticles?. Pharmaceutical Research, 2008, 25, 1696-1701.	1.7	101
362	Preparation of Inhalable Salbutamol Sulphate Using Reactive High Gravity Controlled Precipitation. Journal of Pharmaceutical Sciences, 2008, 97, 944-949.	1.6	34
363	The Influence of Drug Morphology on Aerosolisation Efficiency of Dry Powder Inhaler Formulations. Journal of Pharmaceutical Sciences, 2008, 97, 2780-2788.	1.6	74
364	Cospray Dried Antibiotics for Dry Powder Lung Delivery. Journal of Pharmaceutical Sciences, 2008, 97, 3356-3366.	1.6	67
365	Agglomeration of fine particles subjected to centripetal compaction. Powder Technology, 2008, 184, 122-129.	2.1	62
366	Simple and cost-effective powder disperser for aerosol particle size measurement. Powder Technology, 2008, 187, 27-36.	2.1	25
367	Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. International Journal of Pharmaceutics, 2008, 349, 314-322.	2.6	97
368	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. European Journal of Pharmaceutical Sciences, 2008, 35, 12-18.	1.9	80
369	In Vitro/In VivoComparisons in Pulmonary Drug Delivery. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 77-84.	0.7	129
370	What is the role of particle morphology in pharmaceutical powder aerosols?. Expert Opinion on Drug Delivery, 2008, 5, 909-914.	2.4	58
371	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. Journal of Aerosol Science, 2008, 39, 82-93.	1.8	39
372	Effect of moisture on the electrostatic charge properties of metered dose inhaler aerosols. Journal of Aerosol Science, 2008, 39, 211-226.	1.8	22
373	A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. Journal of Aerosol Science, 2008, 39, 500-509.	1.8	49
374	Preparation and characterisation of controlled release co-spray dried drugâ€“polymer microparticles for inhalation 1: Influence of polymer concentration on physical and in vitro characteristics. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 486-495.	2.0	35
375	Preparation and characterisation of controlled release co-spray dried drugâ€“polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 145-152.	2.0	90
376	Dissolution Kinetic Behavior of Drug Nanoparticles and their Conformity to the Diffusion Model. Langmuir, 2008, 24, 7538-7544.	1.6	14
377	Scanning White-Light Interferometry as a Novel Technique to Quantify the Surface Roughness of Micron-Sized Particles for Inhalation. Langmuir, 2008, 24, 11307-11312.	1.6	25
378	Evaluation on the Use of Confined Liquid Impinging Jets for the Synthesis of Nanodrug Particles. Drug Development and Industrial Pharmacy, 2008, 34, 59-64.	0.9	41

#	Article	IF	Citations
379	Formulation Challenges. , 2008, , 623-636.		1
380	In Vitro/In VivoComparisons in Pulmonary Drug Delivery. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
381	The Use of Organic Vapor Sorption to Determine Low Levels of Amorphous Content in Processed Pharmaceutical Powders. Drug Development and Industrial Pharmacy, 2007, 33, 91-97.	0.9	40
382	The Influence of Mechanical Processing of Dry Powder Inhaler Carriers on Drug Aerosolization Performance. Journal of Pharmaceutical Sciences, 2007, 96, 1331-1341.	1.6	60
383	Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. International Journal of Pharmaceutics, 2007, 331, 93-98.	2.6	66
384	In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review. AAPS PharmSciTech, 2007, 8, 237-248.	1.5	91
385	Influence of Humidity on the Electrostatic Charge and Aerosol Performance of Dry Powder Inhaler Carrier based Systems. Pharmaceutical Research, 2007, 24, 963-970.	1.7	103
386	Influence of Mouthpiece Geometry on the Aerosol Delivery Performance of a Dry Powder Inhaler. Pharmaceutical Research, 2007, 24, 1450-1456.	1.7	101
387	Focused-ion-beam Milling: A Novel Approach to Probing the Interior of Particles Used for Inhalation Aerosols. Pharmaceutical Research, 2007, 24, 1608-1617.	1.7	40
388	Sonocrystallisation of sodium chloride particles for inhalation. Chemical Engineering Science, 2007, 62, 2445-2453.	1.9	61
389	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. Physica B: Condensed Matter, 2007, 394, 315-319.	1.3	8
390	SPECT Imaging for Radioaerosol Deposition and Clearance Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 8-20.	1.2	50
391	Dry Powder Aerosol Delivery Systems: Current and Future Research Directions. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 21-27.	1.2	94
392	Preparation of NaCl Powder Suitable for Inhalation. Industrial & Engineering Chemistry Research, 2006, 45, 4188-4192.	1.8	16
393	Effect of spacers on the electrostatic charge properties of metered dose inhaler aerosols. Journal of Aerosol Science, 2006, 37, 1671-1682.	1.8	27
394	Synthesis and Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the Study of Inhaled Drug Deposition. Australian Journal of Chemistry, 2006, 59, 53.	0.5	7
395	Solubility Prediction of Paracetamol in Binary and Ternary Solvent Mixtures Using Jouyban-Acree Model. Chemical and Pharmaceutical Bulletin, 2006, 54, 428-431.	0.6	69
396	Dry powder aerosol drug deliveryâ€"Opportunities for colloid and surface scientists. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2006, 284-285, 50-55.	2.3	81

#	Article	IF	Citations
397	Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. Journal of Pharmaceutical Sciences, 2006, 95, 1382-1392.	1.6	114
398	Lung Deposition of Mannitol Powder Aerosol in Healthy Subjects. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 522-532.	1.2	27
399	Modeling the Entrainer Effects on Solubility of Solutes in Supercritical Carbon Dioxide. Chemical and Pharmaceutical Bulletin, 2005, 53, 290-295.	0.6	25
400	A Unified Cosolvency Model for Calculating Solute Solubility in Mixed Solvents. Chemical and Pharmaceutical Bulletin, 2005, 53, 634-637.	0.6	52
401	Modeling acid dissociation constant of analytes in binary solvents at various temperatures using Jouybanâ€“Acree model. Thermochimica Acta, 2005, 428, 119-123.	1.2	46
402	Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum. Respirology, 2005, 10, 46-56.	1.3	110
403	Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects*. Respirology, 2005, 10, 442-448.	1.3	23
404	Electrostatic charge characteristics of aerosols produced from metered dose inhalers. Journal of Pharmaceutical Sciences, 2005, 94, 2789-2799.	1.6	65
405	Effect of Amino Acids on the Dispersion of Disodium Cromoglycate Powders. Journal of Pharmaceutical Sciences, 2005, 94, 2289-2300.	1.6	148
406	How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders?. Pharmaceutical Research, 2005, 22, 148-152.	1.7	189
407	The Role of Capsule on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. Pharmaceutical Research, 2005, 22, 923-932.	1.7	100
408	Influence of Air Flow on the Performance of a Dry Powder Inhaler Using Computational and Experimental Analyses. Pharmaceutical Research, 2005, 22, 1445-1453.	1.7	148
409	Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulmonary Pharmacology and Therapeutics, 2005, 18, 83-88.	1.1	31
410	Physical Stability of Salmon Calcitonin Spray-Dried Powders for Inhalation. Journal of Pharmaceutical Sciences, 2004, 93, 792-804.	1.6	86
411	Effect of Design on the Performance of a Dry Powder Inhaler Using Computational Fluid Dynamics. Part 1: Grid Structure and Mouthpiece Length. Journal of Pharmaceutical Sciences, 2004, 93, 2863-2876.	1.6	169
412	A simple relationship between dielectric constant of mixed solvents with solvent composition and temperature. International Journal of Pharmaceutics, 2004, 269, 353-360.	2.6	186
413	Feasibility of preparing nanodrugs by high-gravity reactive precipitation. International Journal of Pharmaceutics, 2004, 269, 267-274.	2.6	131
414	Prediction of aerodynamic diameter of particles with rough surfaces. Powder Technology, 2004, 147, 64-78.	2.1	49

#	Article	IF	Citations
415	Effect of Mouthpiece Washing on Aerosol Performance of CFCâ€Free Ventolinâ„¢. Journal of Asthma, 2004, 41, 721-727.	0.9	6
416	Electrostatic charge characterization of pharmaceutical aerosols using electrical low-pressure impaction (ELPI). Journal of Aerosol Science, 2004, 35, 755-764.	1.8	86
417	Airway Hyperresponsiveness to Bronchial Mannitol. Chest, 2004, 126, 319-320.	0.4	1
418	Coughing During Mannitol Challenge Is Associated With Asthma. Chest, 2004, 125, 1985-1992.	0.4	56
419	Generation of Fine Powders of Recombinant Human Deoxyribonuclease Using the Aerosol Solvent Extraction System. Pharmaceutical Research, 2003, 20, 2028-2035.	1.7	24
420	Predicting electrophoretic mobility of beta-blockers in a water-methanol based electrolyte system. Chromatographia, 2003, 57, 191-195.	0.7	19
421	Novel alternative methods for the delivery of drugs for the treatment of asthma. Advanced Drug Delivery Reviews, 2003, 55, 793-805.	6.6	138
422	Comparison of different algorithms to calculate electrophoretic mobility of analytes as a function of binary solvent composition. Electrophoresis, 2003, 24, 1596-1602.	1.3	4
423	Mathematical representation of electrophoretic mobility of basic drugs in ternary solvent buffers in capillary zone electrophoresis. Journal of Chromatography A, 2003, 994, 191-198.	1.8	11
424	Calculation of electrophoretic mobility in ternary solvent electrolyte systems. Journal of Pharmaceutical and Biomedical Analysis, 2003, 32, 203-208.	1.4	5
425	Inhalation drug delivery devices and emerging technologies. Expert Opinion on Therapeutic Patents, 2003, 13, 1333-1343.	2.4	35
426	Limitation of Determination of Surface Fractal Dimension Using N2Adsorption Isotherms and Modified Frenkelâ˜'Halseyâ˜'Hill Theory. Langmuir, 2003, 19, 2632-2638.	1.6	96
427	Mannitol as a Challenge Test to Identify Exercise-induced Bronchoconstriction in Elite Athletes. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 534-537.	2.5	115
428	Sensitivity and Validity of Three Bronchial Provocation Tests To Demonstrate the Effect of Inhaled Corticosteroids in Asthma. Chest, 2003, 124, 1341-1349.	0.4	64
429	Responsiveness to Three Bronchial Provocation Tests in Patients With Asthma. Chest, 2003, 124, 2171-2177.	0.4	49
430	Inhalation Challenge With Bovine Dander Allergens. Chest, 2003, 124, 383-391.	0.4	28
431	Use of Aerosols for Bronchial Provocation Testing in the Laboratory: Where We Have Been and Where We Are Going. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 313-324.	1.2	17
432	Changes in Lung Deposition of Aerosols due to Hygroscopic Growth: A Fast SPECT Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 307-311.	1.2	37

#	Article	IF	Citations
433	Effects of terbutaline in combination with mannitol on mucociliary clearance. European Respiratory Journal, 2002, 20, 1423-1429.	3.1	15
434	A Cosolvency Model to Predict Solubility of Drugs at Several Temperatures from a Limited Number of Solubility Measurements.. Chemical and Pharmaceutical Bulletin, 2002, 50, 594-599.	0.6	47
435	Solubility Prediction of Anthracene in Mixed Solvents Using a Minimum Number of Experimental Data.. Chemical and Pharmaceutical Bulletin, 2002, 50, 21-25.	0.6	41
436	The Role of Particle Properties in Pharmaceutical Powder Inhalation Formulations. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 325-330.	1.2	82
437	Calculation of electrophoretic mobility in mixed solvent buffers in capillary zone electrophoresis using a mixture response surface method. Analyst, The, 2002, 127, 1188-1192.	1.7	11
438	Characterization of pharmaceutical powder inhalers: estimation of energy input for powder dispersion and effect of capsule device configuration. Journal of Aerosol Science, 2002, 33, 999-1008.	1.8	37
439	A Solid-State NMR Study of Protein Mobility in Lyophilized Proteinâ€“Sugar Powders. Journal of Pharmaceutical Sciences, 2002, 91, 943-951.	1.6	40
440	Solubility Prediction in Supercritical CO2 Using Minimum Number of Experiments. Journal of Pharmaceutical Sciences, 2002, 91, 1287-1295.	1.6	64
441	Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology, 2002, 7, 37-44.	1.3	73
442	Mathematical representation of solute solubility in supercritical carbon dioxide using empirical expressions. Journal of Supercritical Fluids, 2002, 24, 19-35.	1.6	166
443	A model to represent solvent effects on the chemical stability of solutes in mixed solvent systems. International Journal of Pharmaceutics, 2002, 243, 167-172.	2.6	23
444	Mathematical representation of apparent dissociation constants in aqueousâ€“organic solvent mixtures. International Journal of Pharmaceutics, 2002, 246, 135-142.	2.6	25
445	Effect of powder polydispersity on aerosol generation. Journal of Pharmacy and Pharmaceutical Sciences, 2002, 5, 162-8.	0.9	44
446	Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects. Respiration Physiology, 2001, 124, 141-150.	2.8	21
447	In Vitro Aerosol Performance and Dose Uniformity between the ForadileÂ® AerolizerÂ® and the OxisÂ® TurbuhalerÂ®. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2001, 14, 495-501.	1.2	56
448	Solubility Prediction for Furosemide in Water-Cosolvent Mixtures Using the Minimum Number of Experiments. Drug Development and Industrial Pharmacy, 2001, 27, 577-583.	0.9	39
449	Pharmaceutical Dry Powder Aerosol Delivery. KONA Powder and Particle Journal, 2001, 19, 46-56.	0.9	4
450	Recent Applications of Supercritical Fluid Technology to Pharmaceutical Powder Systems. KONA Powder and Particle Journal, 2001, 19, 57-70.	0.9	10

#	Article	IF	Citations
451	Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. European Respiratory Journal, 2001, 18, 444-450.	3.1	66
452	Aerosol deposition and clearance measurement: a novel technique using dynamic SPET. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1365-1372.	2.2	38
453	Mathematical representation of electrophoretic mobility in mixed aqueous-methanolic buffers in capillary zone electrophoresis. Journal of Separation Science, 2001, 13, 346-350.	1.0	6
454	Use of solid corrugated particles to enhance powder aerosol performance. Pharmaceutical Research, 2001, 18, 1570-1577.	1.7	209
455	The 24-h Effect of Mannitol on the Clearance of Mucus in Patients With Bronchiectasis. Chest, 2001, 119, 414-421.	0.4	90
456	Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 406-412.	2.5	302
457	Fexofenadine Decreases Sensitivity to and Montelukast Improves Recovery from Inhaled Mannitol. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1420-1425.	2.5	87
458	Inhaled mannitol identifies methacholine-responsive children with active asthma. , 2000, 29, 291-298.		31
459	Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. International Journal of Pharmaceutics, 2000, 206, 75-83.	2.6	74
460	The effect of spacers on the delivery of metered dose aerosols of nedocromil sodium and disodium cromoglycate. International Journal of Pharmaceutics, 2000, 200, 87-91.	2.6	12
461	Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharmaceutical Research, 2000, 17, 1360-1366.	1.7	82
462	Nedocromil Sodium Inhibits Responsiveness to Inhaled Mannitol in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 2096-2099.	2.5	45
463	Micronization by Rapid Expansion of Supercritical Solutions to Enhance the Dissolution Rates of Poorly Water-Soluble Pharmaceuticals. Industrial & Engineering Chemistry Research, 2000, 39, 4794-4802.	1.8	236
464	Inhalation of Dry Powder Mannitol Improves Clearance of Mucus in Patients with Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1843-1848.	2.5	128
465	Development of a mathematical model for the water distribution in freeze-dried solids. Pharmaceutical Research, 1999, 16, 660-665.	1.7	13
466	Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Pharmaceutical Research, 1999, 16, 1098-1103.	1.7	103
467	Deposition of aqueous aerosol of technetium-99m diethylene triamine penta-acetic acid generated and delivered by a novel system (AER x) in healthy subjects. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 320-327.	3.3	28
468	Drug delivery: A key factor in realising the full therapeutic potential of drugs. Drug Development Research, 1999, 46, 316-327.	1.4	49

#	Article	IF	Citations
469	The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal, 1999, 14, 678.	3.1	164
470	A solid-state NMR study of protein hydration and stability. Pharmaceutical Research, 1998, 15, 1816-1821.	1.7	47
471	Influence of Flow Rate on Aerosol Particle Size Distributions from Pressurized and Breath-Actuated Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 1998, 11, 231-245.	1.2	37
472	Solid State Characterization of Spray-Dried Powders of Recombinant Human Deoxyribonuclease (RhDNase)â€. Journal of Pharmaceutical Sciences, 1998, 87, 647-654.	1.6	38
473	Inhalation of dry-powder mannitol increases mucociliary clearance. European Respiratory Journal, 1997, 10, 2449-2454.	3.1	94
474	Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharmaceutical Research, 1997, 14, 431-437.	1.7	123
475	Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical modeling. Journal of Applied Physiology, 1996, 81, 374-383.	1.2	46
476	Effects of additives on heat denaturation of rhDNase in solutions. Pharmaceutical Research, 1996, 13, 756-761.	1.7	17
477	Aggregation of rhDNase occurred during the compression of KBr pellets used for FTIR spectroscopy. Pharmaceutical Research, 1996, 13, 238-242.	1.7	45
478	Physicochemical Characterization of a New Respirable Form of Nedocromil. Journal of Pharmaceutical Sciences, 1995, 84, 692-696.	1.6	28
479	Mucociliary clearance in patients with cystic fibrosis and in normal subjects.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 66-71.	2.5	181
480	Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract. European Respiratory Journal, 1994, 7, 1483-1489.	3.1	28
481	Dissolution studies of hexamethylmelamine. International Journal of Pharmaceutics, 1993, 95, 143-151.	2.6	3
482	Application of the periodic bond chain (PBC) theory and attachment energy consideration to derive the crystal morphology of hexamethylmelamine. Pharmaceutical Research, 1993, 10, 1052-1058.	1.7	60
483	Preparation of Radiolabeled Materials for Studies of Deposition of Fibers in the Human Respiratory Tract. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 1993, 6, 241-249.	1.2	3
484	Use of Single Photon Emission Computed Tomography in Aerosol Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 1993, 6, 23-36.	1.2	23
485	Crystal Structures of a New Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4- pyridone, and its Solvates with Acetic Acid and Formic Acid. Journal of Pharmaceutical Sciences, 1992, 81, 353-358.	1.6	9
486	Studies of the mechanism of crystal growth of hexamethylmelamine II. Rates of growth of the crystal faces. Journal of Crystal Growth, 1991, 108, 751-758.	0.7	2

#	Article	IF	Citations
487	Methotrexate: Existence of different types of solid. International Journal of Pharmaceutics, 1991, 68, 179-190.	2.6	15
488	Solid State Properties of an Oral Iron Chelator, 1,2-Dimethyl-3-hydroxy-4-pyridone, and Its Acetic Acid Solvate. I: Physicochemical Characterization, Intrinsic Dissolution Rate, and Solution Thermodynamics. Journal of Pharmaceutical Sciences, 1991, 80, 677-685.	1.6	18
489	Studies of the mechanism of crystal growth of hexamethylmelamine. Journal of Crystal Growth, 1990, 104, 355-364.	0.7	5
490	Respirable Form of Crystals of Cromoglycic Acid. Journal of Pharmaceutical Sciences, 1989, 78, 176-180.	1.6	31
491	Serendipitous preparation of crystals of methotrexate and attempts to modify its crystal habit. Journal of Crystal Growth, 1989, 94, 488-498.	0.7	9
492	Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals. International Journal of Pharmaceutics, 1989, 57, 117-124.	2.6	43
493	Aerodynamic properties of elongated particles of cromoglycic acid. Journal of Aerosol Science, 1989, 20, 157-168.	1.8	58
494	Hexamethylmelamine: a study of solvation and crystallisation. Journal of the Chemical Society Perkin Transactions II, 1987, , 1747.	0.9	8
495	Crystal and molecular structure of methotrexate. Journal of the American Chemical Society, 1986, 108, 2103-2105.	6.6	24
496	Excipients: Powders and Solid Dosage Forms. , 0, , 3350-3359.		0